Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07308236 · ClinicalTrials.gov registry record · Phase 1

A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants

A Phase 1 study of Healthy Volunteers, sponsored by Eisai.

Recruiting
Registry status
Phase 1
Development phase
10
Enrollment target
1
Study location

NCT07308236 is a Phase 1 study of Healthy Volunteers that is actively recruiting participants, run by Eisai. The registered enrollment target is 10 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07308236, a Phase 1 study of Healthy Volunteers, is actively recruiting participants, sponsored by Eisai.

RECRUITING
Registry status
Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

The primary purpose of this study is to determine the metabolism and excretion of \[14C\]E2086 in healthy male participants.

Conditions Studied

Interventions

  • DRUG E2086

Study Locations (1)

Wisconsin

  • Fortrea Clinical Research Unit Inc. - Madison

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2025-12-31
Est. Completion 2026-02-23
Phase Phase 1

Sponsor

Eisai

287 total trials

What the Registry Record Tells You About NCT07308236

The ClinicalTrials.gov registry entry for NCT07308236 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (98% lower). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which E2086 is the first listed.

NCT07308236 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT07308236 about?

NCT07308236 is a clinical study titled "A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants". The primary purpose of this study is to determine the metabolism and excretion of \[14C\]E2086 in healthy male participants.

What is the current status of trial NCT07308236?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-12-31. Estimated completion is 2026-02-23.

What conditions does trial NCT07308236 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT07308236?

The interventions under investigation include: E2086 (DRUG).

Who is sponsoring clinical trial NCT07308236?

This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07308236 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.